EMA's CHMP recommends against Nektar's Onzeald

EMA’S CHMP recommended against approval of an MAA for Onzeald etirinotecan pegol (NKTR-102) from Nektar Therapeutics (NASDAQ:NKTR) to treat advanced breast cancer with brain metastases. The agency sa...